StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Up 2.7 %

Shares of TTNP stock opened at $6.88 on Wednesday. Titan Pharmaceuticals has a 12-month low of $5.00 and a 12-month high of $16.60. The firm has a fifty day moving average of $7.27 and a 200-day moving average of $7.05. The firm has a market capitalization of $6.26 million, a price-to-earnings ratio of -0.84 and a beta of 1.32.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.